JILL EASLEY: Open Payments
NPI 1891100970 · MADISON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,984 in 136 payments from 29 companies in 2025. Trend: 2023 $3,060 · 2024 $2,650 · 2025 $2,984
Food & beverage: $2,984
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $404 |
| Astellas Pharma US Inc | 10 | $339 |
| Axsome Therapeutics, Inc. | 4 | $240 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 11 | $229 |
| AstraZeneca Pharmaceuticals LP | 14 | $222 |
| PFIZER INC. | 10 | $203 |
| Lilly USA, LLC | 19 | $199 |
| Novo Nordisk Inc | 9 | $173 |
| Teva Pharmaceuticals USA, Inc. | 1 | $124 |
| Abbott Laboratories | 1 | $114 |
Products named: Veozah, UBRELVY, XIFAXAN, Auvelity, FARXIGA, NURTEC ODT, MOUNJARO, REXULTI.
Industry payments across MS — which companies pay providers there.
